sublingual tirzepatide clinical trial Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 What are the sublingual and

Always double-check your dose before administration

But the charts in this guide will get you started with confidence

Data Extraction Data were extracted from each eligible study included in the meta-analysis: study title, primary author, year of publication, sample size, patient demographics study details (single vs multicenter), study duration, average HbA1c, duration of diabetes, and tirzepatide dose assessed

It is a dual GIP (Glucose-dependent insulinotropic peptide) and GLP-1 (glucagon-like peptide-1) receptor agonist that aids in weight loss and blood sugar management

The clinical data supports this calculation